BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$85.38 USD
+1.29 (1.53%)
Updated Jul 22, 2024 11:06 AM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BMRN 85.38 +1.29(1.53%)
Will BMRN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Is The Options Market Predicting A Spike In BioMarin Pharmaceutical (BMRN) Stock?
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Other News for BMRN
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Parnassus Mid Cap Fund Q2 2024 Investment Commentary
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Wall Street Analysts Are Bullish on Top Healthcare Picks